Anticancer activities of epigallocatechin-3-gallate against cholangiocarcinoma cells

OncoTargets and Therapy

Volumn 10, Issue , 2017, Pages 137-144

  Kwak, Tae Won ^a   Park, Su Bum ^b   Kim, Hyun Jung ^c   Jeong, Young IL ^d   Kang, Dae Hwan ^a,b  

^a Pusan National University Yangsan Hospital   (South Korea)

^b Pusan National University School of Medicine   (South Korea)

^c Genewel Co Ltd   (South Korea)

^d Pusan National University School of Medicine   (South Korea)

Author keywords

Cholangiocarcinoma; Epigallocatechin 3 gallate; Invasion; Matrix metalloproteinases 2; Thermosensitive hydrogel

Indexed keywords

CASPASE; CYCLINE; CYTOCHROME C; EPIGALLOCATECHIN GALLATE; GELATINASE A; GELATINASE B; NOTCH1 RECEPTOR; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BILE DUCT CARCINOMA; CANCER INHIBITION; CARCINOMA CELL; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VIVO STUDY; LOCAL THERAPY; MOUSE; NONHUMAN; TUMOR XENOGRAFT; WOUND HEALING;

EID: 85007579960     PISSN: None     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S112364     Document Type: Article

References (33)

1. Shankar S, Ganapathy S, Srivastava RK. Green tea polyphenols: biology and therapeutic implications in cancer. Front Biosci. 2007; 12: 4881-4899.
2. Liao S, Umekita Y, Guo J, Kokontis JM, Hiipakka RA. Growth inhibition and regression of human prostate and breast tumors in athymic mice by tea epigallocatechin gallate. Cancer Lett. 1995; 96(2): 239-243.
3. Thangapazham RL, Singh AK, Sharma A, Warren J, Gaddipati JP, Maheshwari RK. Green tea polyphenols and its constituent epigallocatechin gallate inhibits proliferation of human breast cancer cells in vitro and in vivo. Cancer Lett. 2007; 245(1-2): 232-241.
4. Das A, Banik NL, Ray SK. Flavonoids activated caspases for apoptosis in human glioblastoma T98G and U87MG cells but not in human normal astrocytes. Cancer. 2010; 116(1): 164-176.
5. Qiao Y, Cao J, Xie L, Shi X. Cell growth inhibition and gene expression regulation by (-)-epigallocatechin-3-gallate in human cervical cancer cells. Arch Pharm Res. 2009; 32(9): 1309-1315.
6. Philips BJ, Coyle CH, Morrisroe SN, Chancellor MB, Yoshimura N. Induction of apoptosis in human bladder cancer cells by green tea catechins. Biomed Res. 2009; 30(4): 207-215.
7. Min NY, Kim JH, Choi JH, et al. Selective death of cancer cells by preferential induction of reactive oxygen species in response to (-)-epigallocatechin-3-gallate. Biochem Biophys Res Commun. 2012; 421(1): 91-97.
8. Senggunprai L, Kukongviriyapan V, Prawan A, Kukongviriyapan U. Quercetin and EGCG exhibit chemopreventive effects in cholangiocarcinoma cells via suppression of JAK/STAT signaling pathway. Phytother Res. 2014; 28(6): 841-848.
9. Sartor L, Pezzato E, Donà M, et al. Prostate carcinoma and green tea: (-)epigallocatechin-3-gallate inhibits inflammation-triggered MMP-2 activation and invasion in murine TRAMP model. Int J Cancer. 2004; 112(5): 823-829.
10. Ramadass SK, Anantharaman NV, Subramanian S, Sivasubramanian S, Madhan B. Paclitaxel/epigallocatechin gallate coloaded liposome: a synergistic delivery to control the invasiveness of MDA-MB-231 breast cancer cells. Colloids Surf B Biointerfaces. 2015; 125: 65-72.
11. Farabegoli F, Papi A, Orlandi M. (-)-Epigallocatechin-3-gallate down-regulates EGFR, MMP-2, MMP-9 and EMMPRIN and inhibits the invasion of MCF-7 tamoxifen-resistant cells. Biosci Rep. 2011; 31(2): 99-108.
12. Benelli R, Venè R, Bisacchi D, Garbisa S, Albini A. Anti-invasive effects of green tea polyphenol epigallocatechin-3-gallate (EGCG), a natural inhibitor of metallo and serine proteases. Biol Chem. 2002; 383(1): 101-105.
13. Baliga MS, Meleth S, Katiyar SK. Growth inhibitory and antimetastatic effect of green tea polyphenols on metastasis-specific mouse mammary carcinoma 4T1 cells in vitro and in vivo systems. Clin Cancer Res. 2005; 11(5): 1918-1927.
14. Li H, Li Z, Xu YM, et al. Epigallocatechin-3-gallate induces apoptosis, inhibits proliferation and decreases invasion of glioma cell. Neurosci Bull. 2014; 30(1): 67-73.
15. Ustundag Y, Bayraktar Y. Cholangiocarcinoma: a compact review of the literature. World J Gastroenterol. 2008; 14(42): 6458-6466.
16. Sandhu DS, Roberts LR. Diagnosis and management of cholangiocarcinoma. Curr Gastroenterol Rep. 2008; 10(1): 43-52.
17. Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology. 2001; 33(6): 1353-1357.
18. Lim JH. Cholangiocarcinoma: morphologic classification according to growth pattern and imaging findings. AJR Am J Roentgenol. 2003; 181(3): 819-827.
19. Singh P, Patel T. Advances in the diagnosis, evaluation and management of cholangiocarcinoma. Curr Opin Gastroenterol. 2006; 22(3): 294-299.
20. Khan SA, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P, Thomas HC. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol. 2002; 37(6): 806-813.
21. Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet. 2005; 366: 1303-1314.
22. Bhuiya MR, Nimura Y, Kamiya J, et al. Clinicopathologic studies on perineural invasion of bile duct carcinoma. Ann Surg. 1992; 215(4): 344-349.
23. Soares KC, Kamel I, Cosgrove DP, Herman JM, Pawlik TM. Hilar cholangiocarcinoma: diagnosis, treatment options, and management. Hepatobiliary Surg Nutr. 2014; 3(1): 18-34.
24. Shen FZ, Zhang BY, Feng YJ, et al. Current research in perineural invasion of cholangiocarcinoma. J Exp Clin Cancer Res. 2010; 29: 24.
25. Thomas MB. Biological characteristics of cancers in the gallbladder and biliary tract and targeted therapy. Crit Rev Oncol Hematol. 2007; 61(1): 44-51.
26. Thomas MB. Systemic and targeted therapy for biliary tract tumors and primary liver tumors. Surg Oncol Clin N Am. 2014; 23(2): 369-381.
27. Kuhlmann JB, Blum HE. Locoregional therapy for cholangiocarcinoma. Curr Opin Gastroenterol. 2013; 29(3): 324-328.
28. Zhang Y, Owusu L, Duan W, et al. Anti-metastatic and differential effects on protein expression of epigallocatechin-3-gallate in HCCLM6 hepatocellular carcinoma cells. Int J Mol Med. 2013; 32(4): 959-964.
29. Zhang Y, Duan W, Owusu L, Wu D, Xin Y. Epigallocatechin-3-gallate induces the apoptosis of hepatocellular carcinoma LM6 cells but not non-cancerous liver cells. Int J Mol Med. 2015; 35(1): 117-124.
30. Hai S, Kubo S, Uenishi T, et al. Postoperative survival in intrahepatic cholangiocarcinoma showing intraductal growth. Hepatogastroenterology. 2005; 52(62): 374-377.
31. Khan N, Bharali DJ, Adhami VM, et al. Oral administration of naturally occurring chitosan-based nanoformulated green tea polyphenol EGCG effectively inhibits prostate cancer cell growth in a xenograft model. Carcinogenesis. 2014; 35(2): 415-423.
32. Fujiki H, Sueoka E, Watanabe T, Suganuma M. Synergistic enhancement of anticancer effects on numerous human cancer cell lines treated with the combination of EGCG, other green tea catechins, and anticancer compounds. J Cancer Res Clin Oncol. 2015; 141(9): 1511-1522.
33. Lang M, Henson R, Braconi C, Patel T. Epigallocatechin-gallate modulates chemotherapy-induced apoptosis in human cholangiocarcinoma cells. Liver Int. 2009; 29(5): 670-677.